Who are Neostigmine and Glycopyrrolate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neostigmine w/ Glycopyrrolate, Neostigmine + Glycopyrrolate, neostigmine/glycopyrolate, Neostigmine with glycopyrrolate, neostigmine and glycopyrrolate or atropine, Combination of Neostigmine and Glycopyrrolate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/neostigmine-and-glycopyrrolate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Neostigmine and Glycopyrrolate — Competitive Intelligence Brief

Neostigmine and Glycopyrrolate (Neostigmine and Glycopyrrolate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor with anticholinergic agent. Area: Neurology.

marketed Cholinesterase inhibitor with anticholinergic agent Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Neostigmine and Glycopyrrolate (Neostigmine and Glycopyrrolate) — James J. Peters Veterans Affairs Medical Center. Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Neostigmine and Glycopyrrolate TARGET	Neostigmine and Glycopyrrolate	James J. Peters Veterans Affairs Medical Center	marketed	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
Neostigmine w/ Glycopyrrolate	Neostigmine w/ Glycopyrrolate	University of Texas Southwestern Medical Center	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate)
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
neostigmine/glycopyrolate	neostigmine/glycopyrolate	Henry Ford Health System	marketed	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate)
Neostigmine with glycopyrrolate	Neostigmine with glycopyrrolate	The Cleveland Clinic	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase; muscarinic acetylcholine receptors
neostigmine and glycopyrrolate or atropine	neostigmine and glycopyrrolate or atropine	Merck Sharp & Dohme LLC	phase 3	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate/atropine)
Combination of Neostigmine and Glycopyrrolate	Combination of Neostigmine and Glycopyrrolate	James J. Peters Veterans Affairs Medical Center	phase 3	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cholinesterase inhibitor with anticholinergic agent class)

James J. Peters Veterans Affairs Medical Center · 2 drugs in this class
Henry Ford Health System · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Neostigmine and Glycopyrrolate — Competitive Intelligence Brief. https://druglandscape.com/ci/neostigmine-and-glycopyrrolate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab